D
Vivos Therapeutics, Inc.
VVOS
$2.57
-$0.06-2.28%
D
Sell
1/21/2025Upgraded
Vivos Therapeutics, Inc. (VVOS) was upgraded to D- from E+ on 1/21/2025 due to an increase in the volatility index and total return index.
Vivos Therapeutics, Inc. (VVOS) was upgraded to D- from E+ on 1/21/2025 due to an increase in the volatility index and total return index.
E
Sell
1/6/2025Downgrade
Vivos Therapeutics, Inc. (VVOS) was downgraded to E+ from D- on 1/6/2025 due to a decline in the volatility index.
Vivos Therapeutics, Inc. (VVOS) was downgraded to E+ from D- on 1/6/2025 due to a decline in the volatility index.
D
Sell
12/20/2024Upgraded
Vivos Therapeutics, Inc. (VVOS) was upgraded to D- from E+ on 12/20/2024 due to an increase in the total return index, volatility index and growth index. Earnings per share increased from -$0.5978 to -$0.3954.
Vivos Therapeutics, Inc. (VVOS) was upgraded to D- from E+ on 12/20/2024 due to an increase in the total return index, volatility index and growth index. Earnings per share increased from -$0.5978 to -$0.3954.
E
Sell
3/14/2023Downgrade
Vivos Therapeutics, Inc. (VVOS) was downgraded to E+ from D- on 03/14/2023.
Vivos Therapeutics, Inc. (VVOS) was downgraded to E+ from D- on 03/14/2023.
D
Sell
3/6/2023Downgrade
Vivos Therapeutics, Inc. (VVOS) was downgraded to D- from D on 3/6/2023 due to a decline in the volatility index.
Vivos Therapeutics, Inc. (VVOS) was downgraded to D- from D on 3/6/2023 due to a decline in the volatility index.
D
Sell
2/9/2023Upgraded
Vivos Therapeutics, Inc. (VVOS) was upgraded to D from E+ on 02/09/2023.
Vivos Therapeutics, Inc. (VVOS) was upgraded to D from E+ on 02/09/2023.
E
Sell
2/8/2023Downgrade
Vivos Therapeutics, Inc. (VVOS) was downgraded to E+ from D on 02/08/2023.
Vivos Therapeutics, Inc. (VVOS) was downgraded to E+ from D on 02/08/2023.
D
Sell
1/20/2023Upgraded
Vivos Therapeutics, Inc. (VVOS) was upgraded to D from D- on 1/20/2023 due to an increase in the volatility index and total return index.
Vivos Therapeutics, Inc. (VVOS) was upgraded to D from D- on 1/20/2023 due to an increase in the volatility index and total return index.
D
Sell
1/5/2023Downgrade
Vivos Therapeutics, Inc. (VVOS) was downgraded to D- from D on 1/5/2023 due to a decline in the volatility index and valuation index.
Vivos Therapeutics, Inc. (VVOS) was downgraded to D- from D on 1/5/2023 due to a decline in the volatility index and valuation index.
D
Sell
12/21/2022Upgraded
Vivos Therapeutics, Inc. (VVOS) was upgraded to D from D- on 12/21/2022 due to an increase in the volatility index, growth index and valuation index. EBIT increased 22.36% from -$6.96M to -$5.41M, earnings per share increased from -$0.3293 to -$0.2559, and total revenue increased 1.48% from $4.18M to $4.25M.
Vivos Therapeutics, Inc. (VVOS) was upgraded to D from D- on 12/21/2022 due to an increase in the volatility index, growth index and valuation index. EBIT increased 22.36% from -$6.96M to -$5.41M, earnings per share increased from -$0.3293 to -$0.2559, and total revenue increased 1.48% from $4.18M to $4.25M.
D
Sell
12/1/2022Downgrade
Vivos Therapeutics, Inc. (VVOS) was downgraded to D- from D on 12/1/2022 due to a decline in the volatility index and total return index.
Vivos Therapeutics, Inc. (VVOS) was downgraded to D- from D on 12/1/2022 due to a decline in the volatility index and total return index.
D
Sell
9/19/2022Upgraded
Vivos Therapeutics, Inc. (VVOS) was upgraded to D from D- on 9/19/2022 due to an increase in the volatility index.
Vivos Therapeutics, Inc. (VVOS) was upgraded to D from D- on 9/19/2022 due to an increase in the volatility index.
D
Sell
9/2/2022Downgrade
Vivos Therapeutics, Inc. (VVOS) was downgraded to D- from D on 9/2/2022 due to a decline in the volatility index.
Vivos Therapeutics, Inc. (VVOS) was downgraded to D- from D on 9/2/2022 due to a decline in the volatility index.
D
Sell
7/13/2022Upgraded
Vivos Therapeutics, Inc. (VVOS) was upgraded to D from D- on 7/13/2022 due to an increase in the volatility index.
Vivos Therapeutics, Inc. (VVOS) was upgraded to D from D- on 7/13/2022 due to an increase in the volatility index.
D
Sell
6/27/2022Downgrade
Vivos Therapeutics, Inc. (VVOS) was downgraded to D- from D on 6/27/2022 due to a decline in the volatility index and total return index.
Vivos Therapeutics, Inc. (VVOS) was downgraded to D- from D on 6/27/2022 due to a decline in the volatility index and total return index.
D
Sell
6/9/2022Upgraded
Vivos Therapeutics, Inc. (VVOS) was upgraded to D from D- on 6/9/2022 due to an increase in the volatility index.
Vivos Therapeutics, Inc. (VVOS) was upgraded to D from D- on 6/9/2022 due to an increase in the volatility index.
D
Sell
5/23/2022Downgrade
Vivos Therapeutics, Inc. (VVOS) was downgraded to D- from D on 5/23/2022 due to a decline in the solvency index, total return index and volatility index. The quick ratio declined from 3.43 to 2.82.
Vivos Therapeutics, Inc. (VVOS) was downgraded to D- from D on 5/23/2022 due to a decline in the solvency index, total return index and volatility index. The quick ratio declined from 3.43 to 2.82.
D
Sell
5/16/2022Upgraded
Vivos Therapeutics, Inc. (VVOS) was upgraded to D from E+ on 5/16/2022 due to an increase in the volatility index.
Vivos Therapeutics, Inc. (VVOS) was upgraded to D from E+ on 5/16/2022 due to an increase in the volatility index.
E
Sell
5/13/2022Downgrade
Vivos Therapeutics, Inc. (VVOS) was downgraded to E+ from D on 5/13/2022 due to a decline in the volatility index and total return index.
Vivos Therapeutics, Inc. (VVOS) was downgraded to E+ from D on 5/13/2022 due to a decline in the volatility index and total return index.
D
Sell
5/5/2022Upgraded
Vivos Therapeutics, Inc. (VVOS) was upgraded to D from E+ on 5/5/2022 due to an increase in the volatility index.
Vivos Therapeutics, Inc. (VVOS) was upgraded to D from E+ on 5/5/2022 due to an increase in the volatility index.
E
Sell
5/1/2022Downgrade
Vivos Therapeutics, Inc. (VVOS) was downgraded to E+ from D on 5/1/2022 due to a decline in the volatility index.
Vivos Therapeutics, Inc. (VVOS) was downgraded to E+ from D on 5/1/2022 due to a decline in the volatility index.
D
Sell
4/21/2022Upgraded
Vivos Therapeutics, Inc. (VVOS) was upgraded to D from E+ on 4/21/2022 due to an increase in the total return index and volatility index.
Vivos Therapeutics, Inc. (VVOS) was upgraded to D from E+ on 4/21/2022 due to an increase in the total return index and volatility index.
E
Sell
4/20/2022Downgrade
Vivos Therapeutics, Inc. (VVOS) was downgraded to E+ from D on 4/20/2022 due to a decline in the volatility index.
Vivos Therapeutics, Inc. (VVOS) was downgraded to E+ from D on 4/20/2022 due to a decline in the volatility index.
D
Sell
4/18/2022Upgraded
Vivos Therapeutics, Inc. (VVOS) was upgraded to D from D- on 4/18/2022 due to a noticeable increase in the growth index.
Vivos Therapeutics, Inc. (VVOS) was upgraded to D from D- on 4/18/2022 due to a noticeable increase in the growth index.
D
Sell
11/17/2021Upgraded
Vivos Therapeutics, Inc. (VVOS) was upgraded to D- from E+ on 11/17/2021 due to an increase in the solvency index and total return index.
Vivos Therapeutics, Inc. (VVOS) was upgraded to D- from E+ on 11/17/2021 due to an increase in the solvency index and total return index.
E
Sell
11/8/2021Downgrade
Vivos Therapeutics, Inc. (VVOS) was downgraded to E+ from D- on 11/8/2021 due to a decline in the volatility index, growth index and total return index.
Vivos Therapeutics, Inc. (VVOS) was downgraded to E+ from D- on 11/8/2021 due to a decline in the volatility index, growth index and total return index.
D
Sell
9/1/2021Upgraded
Vivos Therapeutics, Inc. (VVOS) was upgraded to D- from E on 9/1/2021 due to an increase in the valuation index, solvency index and volatility index. The quick ratio increased from 2.16 to 4.04, and debt to equity declined from 0.09 to 0.03.
Vivos Therapeutics, Inc. (VVOS) was upgraded to D- from E on 9/1/2021 due to an increase in the valuation index, solvency index and volatility index. The quick ratio increased from 2.16 to 4.04, and debt to equity declined from 0.09 to 0.03.
E
Sell
6/1/2021Upgraded
Vivos Therapeutics, Inc. (VVOS) was upgraded to E from E- on 6/1/2021 due to a noticeable increase in the growth index and solvency index. Earnings per share increased from -$0.8281 to -$0.19, and total revenue increased 4.26% from $3.31M to $3.45M.
Vivos Therapeutics, Inc. (VVOS) was upgraded to E from E- on 6/1/2021 due to a noticeable increase in the growth index and solvency index. Earnings per share increased from -$0.8281 to -$0.19, and total revenue increased 4.26% from $3.31M to $3.45M.
E
Sell
5/6/2021Downgrade
Vivos Therapeutics, Inc. (VVOS) was downgraded to E- from E on 5/6/2021 due to a large decline in the volatility index and total return index.
Vivos Therapeutics, Inc. (VVOS) was downgraded to E- from E on 5/6/2021 due to a large decline in the volatility index and total return index.
E
Sell
4/15/2021Upgraded
Vivos Therapeutics, Inc. (VVOS) was upgraded to E from E- on 4/15/2021 due to an increase in the volatility index and total return index.
Vivos Therapeutics, Inc. (VVOS) was upgraded to E from E- on 4/15/2021 due to an increase in the volatility index and total return index.
E
Sell
3/31/2021Downgrade
Vivos Therapeutics, Inc. (VVOS) was downgraded to E- from E on 3/31/2021 due to a noticeable decline in the growth index, valuation index and volatility index. Operating cash flow declined 479.3% from -$624.6 to -$3.62M, earnings per share declined from -$0.1636 to -$0.8281, and EBIT declined 60.52% from -$1.82M to -$2.92M.
Vivos Therapeutics, Inc. (VVOS) was downgraded to E- from E on 3/31/2021 due to a noticeable decline in the growth index, valuation index and volatility index. Operating cash flow declined 479.3% from -$624.6 to -$3.62M, earnings per share declined from -$0.1636 to -$0.8281, and EBIT declined 60.52% from -$1.82M to -$2.92M.
E
Sell
3/9/2021None
Vivos Therapeutics, Inc. (VVOS) was downgraded to E from U on 03/09/2021.
Vivos Therapeutics, Inc. (VVOS) was downgraded to E from U on 03/09/2021.
NASDAQ
04/02/2025 4:00PM Eastern
Quotes delayed
